The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome.


No votes yet
 
Related
ROVI announces the commencement of the assessment process to obtain marketing authorisation for Doria® in the European Union
ROVI filed its application for marketing authorisation for Doria® with the European health authorities, the European Medicines Agency (EMA...
2 min
31/01/2020